EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury

Qingling Zhang iD, Yunpeng Zhang iD, Bingxin Xie, Daiqi Liu, Yueying Wang, Zandong Zhou, Yue Zhang, Emma King, Gary Tse, Tong Liu iD

Cancer Innovation · 2023-08 · 2 (4) · 253-264

DOI: 10.1002/cai2.64 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Innovation, online erschienen am 30.03.2023. Verfasst von Qingling Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology The Second Ho…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Doxorubicin is a widely used cytotoxic chemotherapy agent for treating different malignancies. However, its use is associated with dose‐dependent cardiotoxicity, causing irreversible myocardial damage and significantly reducing the patient's quality of life and survival. In this study, an animal model of doxorubicin‐induced cardiomyopathy was used to investigate the pathogenesis of doxorubicin‐induced myocardial injury. This study also investigated a possible treatment strategy for alleviating myocardial injury through resveratrol therapy in vitro.

Methods

Adult male C57BL/6J mice were randomly divided into a control group and a doxorubicin group. Body weight, echocardiography, surface electrocardiogram, and myocardial histomorphology were measured. The mechanisms of doxorubicin cardiotoxicity in H9c2 cell lines were explored by comparing three groups (phosphate‐buffered saline, doxorubicin, and doxorubicin with resveratrol).

Results

Compared to the control group, the doxorubicin group showed a lower body weight and higher systolic arterial pressure, associated with reduced left ventricular ejection fraction and left ventricular fractional shortening, prolonged PR interval, and QT interval. These abnormalities were associated with vacuolation and increased disorder in the mitochondria of cardiomyocytes, increased protein expression levels of α‐smooth muscle actin and caspase 3, and reduced protein expression levels of Mitofusin2 (MFN2) and Sirtuin1 (SIRT1). Compared to the doxorubicin group, doxorubicin + resveratrol treatment reduced caspase 3 and manganese superoxide dismutase, and increased MFN2 and SIRT1 expression levels.

Conclusion

Doxorubicin toxicity leads to abnormal mitochondrial morphology and dysfunction in cardiomyocytes and induces apoptosis by interfering with mitochondrial fusion. Resveratrol ameliorates doxorubicin‐induced cardiotoxicity by activating SIRT1/MFN2 to improve mitochondria function.

Schlagwörter

Stichwörter der Autor:innen

SIRT1 agonistscardio‐oncologydoxorubicin‐induced cardiomyopathymitochondria functionresveratrol

Autor:innen und Institutionen

  • Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology The Second Hospital of Tianjin Medical University Tianjin China.
  • Epidemiology Research Unit, Cardiovascular Analytics Group China-UK Collaboration Hong Kong China.
  • Kent and Medway Medical School Canterbury Kent UK.

ORCID-Profile: Qingling Zhang, Yunpeng Zhang, Tong Liu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Q., Zhang, Y., Xie, B., Liu, D., Wang, Y., Zhou, Z., Zhang, Y., King, E., Tse, G., & Liu, T. (2023). Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury. Cancer Innovation, 2(4), 253-264. https://doi.org/10.1002/cai2.64

Vancouver

Zhang Q, Zhang Y, Xie B, Liu D, Wang Y, Zhou Z, et al. Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury. Cancer Innovation. 2023;2(4):253-264. doi:10.1002/cai2.64

BibTeX
@article{Zhang2023,
  author = {Zhang, Qingling and Zhang, Yunpeng and Xie, Bingxin and Liu, Daiqi and Wang, Yueying and Zhou, Zandong and Zhang, Yue and King, Emma and Tse, Gary and Liu, Tong},
  title = {Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury},
  journal = {Cancer Innovation},
  year = {2023},
  volume = {2},
  number = {4},
  pages = {253--264},
  doi = {10.1002/cai2.64}
}
Kostenlos starten →